Cochrane Corner: The use of anticoagulants in patients hospitalised with COVID-19.
COVID-19
Cochrane Review
anticoagulants
bleeding
prophylactic-dose low-molecular-weight heparin
thromboembolism
Journal
The Southern African journal of critical care : the official journal of the Critical Care Society
ISSN: 2078-676X
Titre abrégé: South Afr J Crit Care
Pays: South Africa
ID NLM: 8801525
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
11
2022
accepted:
28
05
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
In this Cochrane Corner, we highlight the main findings of a Cochrane Review by Flumignan et al. entitled 'Anticoagulants for people hospitalised with COVID-19' and discuss the implications of these findings for research and practice in South Africa. In particular, we underscore the need for additional, high-quality, randomised controlled trials comparing different intensities of anticoagulation in patients with COVID-19 illness. Individuals in the intensive care unit and those hospitalised with another illness who are incidentally found to be infected with SARS-CoV-2 should still only be treated with prophylactic-dose low-molecular-weight heparin. This Cochrane Corner summarises findings in a recent systematic review on the use of anticoagulation in people hospitalised with COVID-19, and provides insights on the implications of these findings for implementation by clinicians in South Africa. It highlights the need for clinicians to balance the benefits and harms of providing an anticoagulant, while considering the patients underlying risk for bleeding and thromboembolism.
Sections du résumé
Background
UNASSIGNED
In this Cochrane Corner, we highlight the main findings of a Cochrane Review by Flumignan et al. entitled 'Anticoagulants for people hospitalised with COVID-19' and discuss the implications of these findings for research and practice in South Africa. In particular, we underscore the need for additional, high-quality, randomised controlled trials comparing different intensities of anticoagulation in patients with COVID-19 illness. Individuals in the intensive care unit and those hospitalised with another illness who are incidentally found to be infected with SARS-CoV-2 should still only be treated with prophylactic-dose low-molecular-weight heparin.
Contributions of the study
UNASSIGNED
This Cochrane Corner summarises findings in a recent systematic review on the use of anticoagulation in people hospitalised with COVID-19, and provides insights on the implications of these findings for implementation by clinicians in South Africa. It highlights the need for clinicians to balance the benefits and harms of providing an anticoagulant, while considering the patients underlying risk for bleeding and thromboembolism.
Identifiants
pubmed: 37547768
doi: 10.7196/SAJCC.2023.v39i2.450
pmc: PMC10399546
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2022, Gloeck et al. Copyright of published material remains in the Authors’ name. This allows authors to use their work for their own non-commercial purposes without seeking permission from the Publisher, subject to properly acknowledging the Journal as the original place of publication.
Déclaration de conflit d'intérêts
Conflicts of interest: TK was a member of the National Essential Medicines List COVID-19 Ministerial Advisory Committee.
Références
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936772
pubmed: 32726134
Cochrane Database Syst Rev. 2022 Mar 4;3:CD013739
pubmed: 35244208
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
J Thromb Haemost. 2020 Jul;18(7):1559-1561
pubmed: 32302453
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Thromb J. 2021 Mar 9;19(1):15
pubmed: 33750409
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Blood Adv. 2022 Sep 13;6(17):4915-4923
pubmed: 35503027
JAMA. 2020 Aug 25;324(8):799-801
pubmed: 32702090